Edwards Lifesciences (NYSE:EW) Releases FY 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 2.900-3.050 for the period, compared to the consensus estimate of 2.870. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating and issued a $98.00 price target (up previously from $95.00) on shares of Edwards Lifesciences in a report on Tuesday. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Evercore ISI reiterated an “outperform” rating and set a $94.00 target price on shares of Edwards Lifesciences in a report on Monday, January 5th. Finally, UBS Group reissued a “neutral” rating and issued a $95.00 price target (up previously from $92.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $96.82.

Edwards Lifesciences Stock Down 0.9%

Edwards Lifesciences stock opened at $84.41 on Friday. The company has a fifty day simple moving average of $85.04 and a 200 day simple moving average of $80.75. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a market cap of $48.98 billion, a P/E ratio of 36.38, a price-to-earnings-growth ratio of 3.25 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the company earned $0.67 EPS. Edwards Lifesciences’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Research analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total value of $971,384.40. Following the completion of the transaction, the vice president directly owned 31,870 shares of the company’s stock, valued at approximately $2,729,984.20. This trade represents a 26.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 57,824 shares of company stock valued at $4,863,323. 1.29% of the stock is owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently bought and sold shares of EW. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter worth approximately $25,000. Rakuten Securities Inc. boosted its stake in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the period. Kelleher Financial Advisors acquired a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $50,000. Chapman Financial Group LLC bought a new stake in Edwards Lifesciences in the 2nd quarter valued at $63,000. Finally, Financial Life Planners acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at $93,000. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.